This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Tonghua Dongbao Pharmaceutical Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Innovations by Chunsheng Leng in Pharmaceutical Development
Introduction
Chunsheng Leng is a notable inventor based in Jilin, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of stable drug formulations. His work is characterized by a focus on improving the stability and efficacy of injectable medications.
Latest Patents
Chunsheng Leng holds a patent for a stable secukinumab injection and its preparation method. This innovative formulation includes 50 mg/ml-300 mg/ml of secukinumab, along with histidine, methionine, a low-sugar alcohol, and polysorbate 80, with water for injection as the balance. The pH of the solution is maintained between 5.0 and 7.0. Stability tests have demonstrated that this formulation is superior to existing commercial varieties, meeting the relevant regulations of the Chinese Pharmacopoeia and showing promising application prospects.
Career Highlights
Chunsheng Leng is associated with Tonghua Dongbao Pharmaceutical Co., Ltd., where he has been instrumental in advancing pharmaceutical innovations. His expertise in drug formulation has contributed to the company's reputation for quality and reliability in the pharmaceutical industry.
Collaborations
Chunsheng Leng has worked alongside talented colleagues, including Depeng Wang and Xindan Fan. Their collaborative efforts have fostered a productive environment for innovation and research within their organization.
Conclusion
Chunsheng Leng's contributions to pharmaceutical development, particularly through his patent for a stable secukinumab injection, highlight his role as a key innovator in the industry. His work not only enhances drug stability but also paves the way for improved therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile